Arianna Calcinotto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8017212/publications.pdf

Version: 2024-02-01

24 papers	2,765 citations	394421 19 h-index	642732 23 g-index
25 all docs	25 docs citations	25 times ranked	4875 citing authors

#	Article	IF	Citations
1	Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747.	1.4	49
2	Role of myeloid-derived suppressor cells in hormone-dependent cancers. Swiss Medical Weekly, 2021, 151, w20483.	1.6	1
3	CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eî¼-TCL1 mice through a CD40L-independent mechanism. Blood Advances, 2021, 5, 2817-2828.	5.2	13
4	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science, 2021, 374, 216-224.	12.6	135
5	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nature Communications, 2021, 12, 7033.	12.8	27
6	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. Cell Reports, 2019, 28, 2156-2168.e5.	6.4	129
7	Cellular Senescence: Aging, Cancer, and Injury. Physiological Reviews, 2019, 99, 1047-1078.	28.8	641
8	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. Cell Reports, 2018, 22, 3006-3020.	6.4	62
9	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications, 2018, 9, 4832.	12.8	144
10	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature, 2018, 559, 363-369.	27.8	258
11	Aging tumour cells to cure cancer: "pro-senescence" therapy for cancer. Swiss Medical Weekly, 2017, 147, w14367.	1.6	16
12	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	30.7	133
13	Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. Cancer Research, 2016, 76, 1781-1791.	0.9	24
14	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. OncoImmunology, 2015, 4, e1008850.	4.6	27
15	Tenascin-C Protects Cancer Stemâ€“like Cells from Immune Surveillance by Arresting T-cell Activation. Cancer Research, 2015, 75, 2095-2108.	0.9	112
16	Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings. Cancer Research, 2013, 73, 3545-3554.	0.9	17
17	Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes. Frontiers in Oncology, 2013, 3, 231.	2.8	132
18	Boosting anticancer vaccines. OncoImmunology, 2013, 2, e25032.	4.6	6

#	Article	IF	Citations
19	Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. OncoImmunology, 2013, 2, e24520.	4.6	38
20	The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. OncoImmunology, 2013, 2, e22058.	4.6	121
21	Wonâ€™t you come on in? How to favor lymphocyte infiltration in tumors. OncoImmunology, 2012, 1, 986-988.	4.6	21
22	Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. Cancer Research, 2012, 72, 2746-2756.	0.9	470
23	Targeting TNF-Î± to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy. Journal of Immunology, 2012, 188, 2687-2694.	0.8	128
24	iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells. PLoS ONE, 2010, 5, e8646.	2.5	61